<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330651</url>
  </required_header>
  <id_info>
    <org_study_id>PC-ECLS Study</org_study_id>
    <nct_id>NCT04330651</nct_id>
  </id_info>
  <brief_title>Post-Surgery Extracorporeal Life Support</brief_title>
  <acronym>PC-ECLS</acronym>
  <official_title>Outcomes' Predictors in Post-Surgery Extracorporeal Life Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sandro Gelsomino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Edvin Prifti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Francesco Cabrucci</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marco Bugetti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orlando Parise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aleksander Dokollari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal Life Support (ECLS) may provide pulmonary and circulatory support for patients
      with acute heart failure refractory to conventional medical therapy. However, indications and
      effectiveness of ECLS engagement post-surgery remains a concern. The investigators sought to
      analyze indications, modality and outcomes of PS-ECLS, to identify predictors of early and
      midterm survival after PS-ECLS. The investigators have recorded prospectively, and analysed
      data of 209 consecutive PS-ECLS patients between January 2004 and December 2018. Demographic
      and clinical data before, during and after PS-ECLS were collected and their influence on
      hospital mortality and outcomes (early and midterm) will analyse. Multivariate analysis of
      pre PS-ECLS implantation factors (as age, female sex , insulin-dependent diabetes, pulmonary
      hypertension, STS, type of surgical procedure data, pre-ECLS blood lactate level) will be
      made for identify prognostic risk factors of in-hospital mortality. Overall survival will be
      analysed, at 6 months,1-year and 5-years, respectively and the factors influencing mild/term
      outcome will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Anticipated">January 31, 2029</completion_date>
  <primary_completion_date type="Actual">March 19, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Evaluate Early, mid and late Survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>At 1 Year after surgery</time_frame>
    <description>mid-time survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>At 5 years after surgery</time_frame>
    <description>late survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognostic factors</measure>
    <time_frame>Early: 1 month after surgery</time_frame>
    <description>Identify early and late negative and positive prognostic factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic Factors</measure>
    <time_frame>Late: 5 years after surgery</time_frame>
    <description>Identify early and late negative and positive prognostic factors</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Extracorporeal Life Support</condition>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <condition>Post Cardiac Arrest Syndrome</condition>
  <condition>Post-cardiac Surgery</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ECLS</intervention_name>
    <description>Emergency application of Extracorporeal Life Support in post-surgical patients</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients underwent cardiac surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients underwent cardiac surgery

        Exclusion Criteria:

          -  Age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Massimo Bonacchi</name>
      <address>
        <city>Florence</city>
        <zip>50144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Bonacchi, MD</last_name>
      <phone>393389855782</phone>
      <email>mbonacchi@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Sandro Gelsomino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edvin Prifti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksander Dokollari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Massimo Bonacchi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>extracorporeal life support</keyword>
  <keyword>ecls</keyword>
  <keyword>ecmo</keyword>
  <keyword>outocome</keyword>
  <keyword>prognostic factors</keyword>
  <keyword>extracorporeal membrane oxygenation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

